Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases

Nuclear Medicine and Biology

Volumn 36, Issue 2, 2009, Pages 129-135

  Ogawa, Kazuma ^a   Kawashima, Hidekazu ^b   Shiba, Kazuhiro ^a   Washiyama, Kohshin ^a   Yoshimoto, Mitsuyoshi ^a   Kiyono, Yasushi ^c,d   Ueda, Masashi ^b,d   Mori, Hirofumi ^a   Saji, Hideo ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bisphosphonate; Bone; DOTA; Palliation; Radiation dose; Yttrium 90

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GADOLINIUM; GALLIUM 67; GALLIUM 68; INDIUM 111; LUTETIUM 177; RHENIUM 186; UNCLASSIFIED DRUG; YTTRIUM; YTTRIUM 90; YTTRIUM 90 CITRATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER PALLIATIVE THERAPY; CHELATION; COMPLEX FORMATION; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; LIGAND BINDING; MALE; METAL BINDING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOBLAST;

ANIMALS; BONE NEOPLASMS; DIPHOSPHONATES; DRUG STABILITY; HETEROCYCLIC COMPOUNDS, 1-RING; ISOTOPE LABELING; MALE; MICE; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 59649125010     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.11.007     Document Type: Article

References (35)

1. Portenoy R.K., Payne D., and Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81 (1999) 129-134
2. Portenoy R.K., and Lesage P. Management of cancer pain. Lancet 353 (1999) 1695-1700
3. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 69 (1997) 1-18
4. Arcangeli G., Giovinazzo G., Saracino B., D'Angelo L., Giannarelli D., and Micheli A. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys 42 (1998) 1119-1126
5. Lewington V.J. Bone-seeking radionuclides for therapy. J Nucl Med 46 Suppl 1 (2005) 38S-47S
6. Kutzner J., Hahn K., Grimm W., Rosler H.P., Eckmann A., and Bender S. Yttrium-90-citrat zur schmerztherapie bei knochenmetastasen ([Yttrium-citrate for pain-therapy by bone metastases]). NUC Compact 21 (1990) 128-132
7. Rosch F., Herzog H., Plag C., Neumaier B., Braun U., Muller-Gartner H.W., et al. Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. Eur J Nucl Med 23 (1996) 958-966
8. Ogawa K., Mukai T., Arano Y., Hanaoka H., Hashimoto K., Nishimura H., et al. Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Labelled Comp Radiopharm 47 (2004) 753-761
9. Ogawa K., Mukai T., Arano Y., Ono M., Hanaoka H., Ishino S., et al. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem 16 (2005) 751-757
10. Ogawa K., Mukai T., Arano Y., Otaka A., Ueda M., Uehara T., et al. Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol 33 (2006) 513-520
11. 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. J Nucl Med 48 (2007) 122-127
12. 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones. Nucl Med Biol 34 (2007) 79-87
13. 186Re-MAG3-HBP), an agent for treatment of painful bone metastases. Eur J Nucl Med Mol Imaging 36 (2009) 115-121
14. de Klerk J.M., van Dieren E.B., van het Schip A.D., Hoekstra A., Zonnenberg B.A., van Dijk A., et al. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med 37 (1996) 38-41
15. 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med 44 (2003) 953-960
16. Stabin M.G., Sparks R.B., and Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46 (2005) 1023-1027
17. de Jong M., Bakker W.H., Krenning E.P., Breeman W.A., van der Pluijm M.E., Bernard B.F., et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 24 (1997) 368-371
18. 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 28 (2001) 426-434
19. Goeckeler W.F., Edwards B., Volkert W.A., Holmes R.A., Simon J., and Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 28 (1987) 495-504
20. Zhang S., Gangal G., and Uludag H. 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem Soc Rev 36 (2007) 507-531
21. Subramanian G., McAfee J.G., Blair R.J., Mehter A., and Connor T. Tc-EHDP: a potential radiopharmaceutical for skeletal imaging. J Nucl Med 13 (1972) 947-950
22. Libson K., Deutsch E., and Barnett B.L. Structural characterization of a technetium-99-diphosphonate complex. Implications for the chemistry of technetium-99m skeletal imaging agents. J Am Chem Soc 102 (1980) 2476-2478
23. Wilson G.M., and Pinkerton T.C. Determination of charge and size of technetium diphosphonate complexes by anion-exchange liquid chromatography. Anal Chem 57 (1985) 246-253
24. Deutsch E., Libson K., Vanderheyden J.L., Ketring A.R., and Maxon H.R. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Nucl Med Biol 13 (1986) 465-477
25. de Klerk J.M., van Dijk A., van het Schip A.D., Zonnenberg B.A., and van Rijk P.P. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 33 (1992) 646-651
26. 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med 47 (2006) 2042-2047
27. 99mTc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation. J Biol Inorg Chem 12 (2007) 667-679
28. 99mTc-EC with aminomethylenediphosphonate in the search for a bone tracer with fast clearance from soft tissue. Bioconjug Chem 13 (2002) 16-22
29. Kubicek V., Rudovsky J., Kotek J., Hermann P., Vander Elst L., Muller R.N., et al. A bisphosphonate monoamide analogue of DOTA: a potential agent for bone targeting. J Am Chem Soc 127 (2005) 16477-16485
30. Meyer J.L., and Nancollas G.H. The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite. Calcif Tissue Res 13 (1973) 295-303
31. van Beek E., Hoekstra M., van de Ruit M., Lowik C., and Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9 (1994) 1875-1882
32. 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med 40 (1999) 1197-1203
33. 153Sm in rats. Appl Radiat Isot 45 (1994) 949-953
34. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum B 14 (1987) 223-232
35. Das T., Chakraborty S., Unni P.R., Banerjee S., Samuel G., Sarma H.D., et al. Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot 57 (2002) 177-184